NCT04199741

PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56

Immuno-PET Imaging of Neuroendocrine Tumors Using 89Zr-DFO-SC16.56, a DLL3-targeting Monoclonal Antibody

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 53 (estimated)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to look at how safe 89Zr-DFO-SC16.56 is, and how it is processed by the body in people with small cell lung cancer.

Conditions

• Small Cell Lung Cancer
• Small Cell Lung Carcinoma

Interventions

Type	Name	Description
DRUG	89Zr-DFO-SC16.56	Injection of 2 mCi of 89Zr-DFO-SC16.56 for Phase I participants. Dose for Phase II will be determined by results from Phase I.
DRUG	SC16.56, Phase I, Cohort 2	7.5mg
DRUG	SC16.56, Phase I, Cohort 3	22.5mg
DRUG	SC16.56, Phase II	Dose for Phase II will be determined by results from Phase I.

Timeline

• Start date: 2019-12-11
• Primary completion: 2026-06-11
• Completion: 2026-06-11
• First posted: 2019-12-16
• Last updated: 2026-01-07

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study